<DOC>
	<DOCNO>NCT02954198</DOCNO>
	<brief_summary>With availability well-studied once-daily formulation tacrolimus , ability achieve true once-daily immunosuppressant regimen along everolimus steroid may finally achievable potential optimize immunosuppression safety efficacy kidney transplantation .</brief_summary>
	<brief_title>Once-daily Regimen With Envarsus® Optimize Immunosuppression Management Outcomes Kidney Transplant Recipients</brief_title>
	<detailed_description>A once-daily immunosuppressant regimen comprise Envarsus-everolimus-prednisone 6-month treatment failure rate non-inferior twice-daily regimen Envarsus-mycophenolate mofetil-prednisone improve patient-reported adherence .</detailed_description>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>1 . Inclusion criterion 1 . Male female adult ( ≥18 year old ) history solitary kidney transplant within 3 month ( ±2 month ) transplant selfreported medication adherence issue , indicate MMAS8 least 1 . 2 . Patients must capable understanding purpose risk study ability give write informed consent willing participate comply study . 3 . Women childbearing potential must negative pregnancy test within 48 hour prior receive study medication . 4 . Women childbearing potential sexually active male must willing use contraception , indicate Section 6 protocol . Subjects reproductive potential ( status post bilateral tubal ligation , bilateral oophorectomy , hysterectomy , vasectomy ) , sexually active , whose current partner ( ) reproductive potential , whose sexual activity exclusively homosexual eligible without require use contraception . 2 . Exclusion criterion 1 . Patients exclude pregnant nursing female male pregnant female partner 2 . Recipient multiple organ transplant 3 . Recipient nonrenal organ 4 . Proteinuria &gt; 800 mg/24 hour 5. eGFR &lt; 30 ml/min 6 . WBC ≤ 2k/mm3 7 . Plt ≤ 50k/mm3 8 . Triglycerides &gt; 500 mg/dL 9 . HIV positive ( HIV ab + ) 10 . Unable tolerate oral medication 11 . Use another investigational product within thirty day prior receive study medication 12 . Acute graft rejection within past month ( Banff 1A high ) receive ABO incompatible donor organ . 13 . A condition disorder , opinion investigator , may adversely affect outcome study safety subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>